Document:

<PAGE>

                                                                   EXHIBIT 10.20

 Amended and Restated Human Glucagon, Analogues of Human Glucagon, Analogs of
                        Human Insulin Letter Agreement

WHEREAS, ZGI, formerly an indirectly wholly owned subsidiary of NN, is engaged
generally in the research and development of biopharmaceutical products;

WHEREAS, NN and ZGI have settled NN's ongoing royalty obligation under this
Agreement for product known as NovoRapid(R), a human insulin analogue, pursuant
to a License Agreement having an effective date of September 28, 2000; and

WHEREAS, NN and ZGI wish to clarify the scope of this Agreement by deleting
analogues of human insulin therefrom;

NOW, THEREFORE, AS OF SEPTEMBER 28, 2000, THE PARTIES AGREE TO RESTATE THEIR
AGREEMENT AS FOLLOWS:

Pursuant to Section 6 of the Agreement dated August 6, 1982, between
ZymoGenetics, Inc. (formerly Zymos Corporation) and Novo Industri A/S (the
"Agreement") and with reference to our discussions at Novo on January 22, 1987,
we write to confirm the Agreement of ZymoGenetics, Inc. to the following terms
and conditions:

     1.  ZymoGenetics, Inc. ("ZYMO") hereby grants to Novo Industri A/S ("NOVO")
     a perpetual, exclusive, irrevocable, worldwide license (with the right to
     sublicense) to manufacture, have manufactured, use and sell Human Glucagon
     and Analogues of Human Glucagon through the use of Insulin Organisms,
     Technical Information and/or any Patents, the terms "Insulin Organisms",
     "Technical Information" and "Patents", having in this document the same
     meanings as in the Agreement.

     2.  In consideration of receiving the aforesaid license, NOVO shall make
     payments to ZYMO as set forth below:

         (a)  Definitions:

              (i)   "Participation Year" shall mean each successive twelve (12)
                    month period commencing on the date of the First Commercial
                    Sale;

              (ii)  "Net Sales" shall gross revenues to the NOVO Group from the
                    sale of Glucagon and/or Analogues of Glucagon produced
                    through the use of Insulin Organisms, Technical Information
                    and/or Patents under this license realized in each
                    participation Year less:

                       -  insurance and delivery charges paid or allowed by the
                       NOVO Group;

                       -  trade and cash discounts and commissions;

[ * ] designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

                       -  returns, credits or allowances; and

                       -  sales and excise taxes, duties or other governmental
                       charges (other than taxes on the NOVO Group's profits).
                       Net sales shall not include sales between members of the
                       NOVO Group.

              (iii) "First Commercial Sale" shall mean with respect to Glucagon
                    or Analogues of Glucagon the first sale of each produced
                    through use of Insulin Organisms, Technical Information
                    and/or Patents under this license by a member of the NOVO
                    Group to any company not a member of the NOVO Group for
                    consideration in an arms-length transaction.

         (b)  Payments:

              An amount with respect to each Participation Year equal to [ * ]
              in aggregate Net Sales of Glucagon and Analogues of Glucagon,
              [ * ] Net Sales.

         (c)  Term:

              The obligation of NOVO to make such payments shall commence with
              respect to each country where Glucagon or Analogues of Glucagon
              are sold under this license on the date of the First Commercial
              Sales of such product and shall continue until December 31, 2000,
              or, subject to the terms of Section 7(b) of the Agreement, for the
              normal life of any Patents licensed in respect of each country,
              whether such normal life is shorter or longer.

         (d)  If NOVO enters into any sublicense, other than a sublicense to a
              member of the NOVO Group, pursuant to the provisions hereof, it
              shall pay to ZYMO [ * ] of the aggregate amount of any royalties
              received by NOVO in connection with such sublicense.

     3.  The provisions of Sections 1(a), (b), (d), (g), (h), (i) and (j), 7
     (except 7(d) and (g)), 10, 11, 12, 13, 14, 15, 16 and 17 of the Agreement
     are incorporated herein by reference and made a part hereof as if fully set
     out herein.  The provisions of Sections 7(m), (n) and (o) shall apply with
     equal force to Human Glucagon and Analogues of Human Glucagon.

[ * ] designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

          IN WITNESS WHEREOF, NOVO and ZYMO have caused this amended and
restated Agreement to be executed in their names by their properly and duly
authorized officers or representatives.

Novo Nordisk A/S

/s/ Lars K. Sorensen                   /s/ ILLEGIBLE
----------------------------------     --------------------------------------
Lars Rebien Sorensen                   Mads Krogsgaard Thomsen
Corporate Executive Vice President     Corporate Vice President, Health Care
                                       Discovery and Pre-Clinical Development

ZymoGenetics, Inc.

/s/ Bruce L.A. Carter
---------------------
Bruce L.A. Carter
President & CEO

[ * ] designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.<PAGE>

                                                                   EXHIBIT 10.21

                License Agreement for Analogues of Human Insulin

This License Agreement of September 28, 2000 (the "Agreement") governs the
transfer of certain rights and obligations of ZymoGenetics, Inc., a Washington
corporation having a principal place of business at 1201 Eastlake Avenue East,
Seattle, Washington 98102 ("ZGI") to Novo Nordisk Health Care AG, a Swiss
corporation having a principal place of business at Untere Heslibachstrasse 46,
CH-8700 Kusnacht, Zurich, Switzerland ("NN").

WHEREAS, ZGI is engaged generally in the research and development of
biopharmaceutical products;

WHEREAS, ZGI and Novo Industri A/S entered into an agreement dated March 13,
1987 concerning human glucagon, analogues of human glucagon and analogues of
human insulin (hereinafter, the "Glucagon and Analogue Agreement");

WHEREAS, Zymos Corporation (the predecessor corporation to ZGI) and Novo
Industri A/S entered into an agreement dated August 6, 1982 concerning human
insulin (hereinafter, the "Insulin Agreement"); and

WHEREAS, ZGI wishes to assign to NN certain rights and obligations under the
Glucagon and Analogue Agreement with regard to analogues of human insulin;

NOW THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

                                   ARTICLE 1
                                  Definitions
                                  -----------

SECTION 1.1.  "Effective Date" means September 28, 2000.
              ----------------

SECTION 1.2.  "Products" means:  the product designated NovoLog(R) in the United
              ----------
States and NovoRapid(R) outside the US and the product not yet on the market
currently designated NN304 by Novo Nordisk A/S, regardless of the territory or
country in which they are sold or under which tradenames or brand names they are
sold.

                                   ARTICLE 2
                                    License
                                    -------

SECTION 2.1.  License.  As of the Effective Date, provided that the exploitation
              --------
fee set forth in ARTICLE 3 is or has been timely paid, ZGI hereby grants to NN a
perpetual, exclusive,

Assignment: NovoRapid

[*]designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

irrevocable, worldwide and fully paid-up license (with the right to sublicense)
to manufacture, have manufactured, use and sell Analogues of Human Insulin
(including but not limited to the Products) through the use of Insulin
Organisms, Technical Information and/or any Patents (including but not limited
to the patents listed in Appendix 1), the terms "Insulin Organisms", "Technical
                         ----------
Information" and "Patents", having in this Agreement the same meanings as
referred to in the Insulin Agreement.

SECTION 2.2.  Other Contractual Relationship.  ZGI and NN agree that the
              -------------------------------
provisions of Sections 1(a), (b), (d), (g), (h), (i) and (j), 7 (i), (j), (k),
(l), (m), (n) and (o), 10 and 11 of the Insulin Agreement shall apply mutatis
mutandis between ZGI and NN in respect of Analogues of Human Insulin and made a
part hereof as if fully set out herein.  The provisions of Sections 7(m), (n)
and (o) shall apply with equal force to Analogues of Human Insulin. ZGI and NN
acknowledge that the Glucagon and Analogue Agreement will be amended and
restated by ZGI and Novo Nordisk A/S in accordance with Appendix 2.

SECTION 2.3.  Maintenance of Patents. ZGI shall be responsible for maintaining
              -----------------------
the Patents and shall bear all costs incurred in connection with such
maintenance.  If  ZGI intends to abandon any Patent, it shall provide NN with at
least thirty (30) days prior written notice of such intention to abandon. NN may
in this event choose to maintain such Patent(s) at its own expense and to have
such Patent(s) transferred to NN, provided that NN reimburses ZGI for ZGI's
documented out of pocket expenses incurred in effectuating such transfer within
thirty (30) days of NN's receipt of ZGI's invoice detailing such expenses.

                                   ARTICLE 3
                               Exploitation Fee
                               ----------------

On, before or within thirty (30) business days after the Effective Date, NN
shall pay to ZGI an exploitation fee of thirteen million six hundred thousand
United States dollars (US$13,600,000) less the amount of any royalty payments
actually received by ZGI from NN or an affiliate of NN during the year 2000 and
before the Effective Date that are attributable to year 2000 Product sales.

Assignment: NovoRapid

[*]designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

                                   ARTICLE 4
                                Indemnification
                                ---------------

SECTION 4.1.  Personal Injury or Property Damage.  NN shall indemnify and hold
              -----------------------------------
ZGI harmless from and against any and all claims, judgments, costs, awards,
expenses (including, but not limited to, any attorney's fees) or liability of
any kind arising out of personal injury or property damage caused or alleged to
be caused by NN's or NN's affiliates' activities pursuant to the Glucagon and
Analogue Agreement relating to the Product.  In addition, NN or NN's affiliates'
shall assume all obligations for warranties and product liability claims that
accompany or result from the sale or use of any Product, and shall indemnify and
hold ZGI harmless from and against any and all claims, judgments, costs, awards,
expenses (including, but not limited to, any attorney's fees) or liability of
any kind arising from customers and relating to such warranty obligations or
product liability claims.  NN's obligation to indemnify ZGI under this SECTION
4.1 shall not apply in case of gross negligence or willful misconduct by ZGI.
 .
SECTION 4.2.  Insurance.  NN shall maintain and cause its affiliates to maintain
              ---------
appropriate product liability insurance with respect to development, manufacture
and sale of Products in such amount as NN or its affiliates customarily
maintains with respect to sales of its other products.  NN and its affiliates
shall maintain such insurance for so long as NN or its affiliate continues to
manufacture or sell Products, and thereafter for so long as NN or its affiliates
customarily maintains insurance with respect to sales of its other products.

SECTION 4.3.  Survival.  The obligations of this ARTICLE 4 shall survive the
              ---------
expiry or termination, for whatever reason, of this Agreement.

                                   ARTICLE 5
                                    General
                                    -------

SECTION 5.1.  Governing Law.  This Agreement shall be governed in all respects
              -------------
by the laws of the State of New York.

SECTION 5.2.  Dispute Resolution.  ZGI and NN will use their best efforts to
              -------------------
settle all matters in dispute amicably. All disputes and differences of any kind
related to this Agreement, which cannot be solved amicably by the Parties, shall
be referred to arbitration as described below. However, before a dispute or
difference is referred to arbitration, the CEO of ZGI and the CEO of Novo
Nordisk A/S (through a request to this extent from NN) shall make a final
attempt to solve the matter amicably.  All disputes arising out of or in
connection with the present contract shall be finally settled under the Rules of
Arbitration of the International Chamber of Commerce by one arbitrator appointed
in accordance with the said Rules. The arbitration shall take place in New York
City and shall be conducted in the English language. The award of the arbitrator
shall be final and binding on both ZGI and NN.  ZGI and NN bind themselves to
carry out the awards of the arbitrator.

SECTION 5.3.  Entire Agreement.  This Agreement constitutes the entire agreement
              ----------------
between the parties and supersedes all prior oral and written agreements,
understandings or arrangements relating to the subject matter hereof.  No
addition to or modification of any provision of this Agreement shall be binding
upon the parties, unless made in writing and signed by a duly authorized
representative of each of the parties.
Assignment: NovoRapid

[*]designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

SECTION 5.4.  Severability.  The parties agree that, if any provision of this
              ------------
Agreement shall for any reason be held to be invalid or unenforceable, such
provision shall be enforced to the maximum extent permitted by law and the
parties' fundamental intentions hereunder, and the remaining provisions hereof
shall not be affected, impaired or invalidated and shall continue in full force
and effect.

SECTION 5.5.  Headings. The article and section headings contained herein are
              --------
for reference only and shall not be considered a part of this Agreement, nor
shall they in any way affect the interpretation hereof.

SECTION 5.6.  Counterparts.  This Agreement may be executed in two or more
              ------------
counterparts each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, NN and ZGI have caused this Agreement to be executed in
their names by their properly and duly authorized officers or representatives.

Signed fter ExtraordinaryShareholders
Meeting and Board Meetings were Held:

Novo Nordisk Health Care AG

/s/ ILLEGIBLE                       /s/ ILLEGIBLE
-------------------------           ---------------------------
Urs N. Pfluger                      Klaus Ehrlick
General Manager                     Board Member

ZymoGenetics, Inc.

/s/ Bruce L.A. Carter
-------------------------
Bruce L.A. Carter
President & CEO

Assignment: NovoRapid

[*]designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.
<PAGE>

                                  APPENDIX 1
                               Licensed Patents

POT Patent family
Patent Family
83-03
[*]

Assignment: NovoRapid

[*]designates portions of this document that have been omitted pursuant to a
request for confidential treatment filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]